ExtremitiesReconSpineSports Medicine

TRENDS | Four Keys to Biopharma High Performer Success

Clear evidence of continued recovery in industry performance: The industry outlook has continued to improve with Enterprise Value rising—driven by improved future growth forecasts. Entry in emerging markets and expedient product launches are still driving the markets, however, investor sentiment has shifted and science-based innovation strategies are now eclipsing diversification.
Some companies are breaking away from the pack through science-based innovation strategies: Our High Performance Business rankings for 2013, based on trailing 12 month Q3-2013 financials, show significant and rapid improvement in performance for a handful of companies, largely driven by recent and upcoming product launches based on scientific innovations versus diversified strategies.
The High Performers are putting science back into Life Sciences: The High Performers are bringing new science to the market in key areas of unmet need as demonstrated by their performance on three key forward-looking metrics:

  • Higher replacement revenue ratio forecast
  • Higher five-year revenue growth forecast
  • Higher proportion of forecast growth from new products
The High Performers are leading the industry in the pivot to the patient:High Performers translate innovative new science into higher growth by excelling in demonstrating outcomes in specific patient groups to payers and carving out a share of stagnant health budgets. High Performers display the following attributes:

  1. Harness collaborative R&D models
  2. Commit to applying science to product launches focused on outcomes for specific patient groups
  3. Use flexible pricing strategies to meet patient population needs
  4. Master multi-channel marketing and patient services that reinforce patient outcomes
  5. Fine tune local operations to succeed in emerging markets

See our full results: Accenture Research Note: Biopharmaceutical High Performance Business Study—2013 Update



Josh Sandberg

Josh Sandberg is the President of Ortho Sales Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *